Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Measuring Stigma Associated with Hepatitis B Virus Infection in Sierra Leone: Validation of an Abridged Berger HIV Stigma Scale

View through CrossRef
ABSTRACT Stigma associated with hepatitis B virus (HBV) is common in endemic countries; however; instruments are lacking to accurately measure HBV-related stigma. We therefore aimed to develop and validate a concise instrument for measuring perceived HBV-related stigma in Sierra Leone. We enrolled 220 people living with HBV (PWHB) aged ≥ 18 years from August to November 2022. The initial Likert-scale instrument entailed 12 items adapted from Berger’s HIV Stigma Scale. We included 4 additional items adapted from the USAID indicators for enacted stigma. The proposed scale’s psychometric properties were assessed. After item reduction, the final HBV Stigma Scale consisted of 10 items and had good internal consistency (overall Cronbach’s α = 0.74), discriminant and construct validity. Exploratory factor analysis produced a 3-dimensional structure accounting for 59.3% of variance: personalized stigma driven by public attitudes (6 items), negative self-image (2 items), and disclosure concerns (2 items). Overall, 72.8% of respondents reported perceived HBV stigma (mean score 29.11 ± 4.14) and a similar a proportion (73.6%) reported at least one instance of enacted stigma. In assessing criterion-related validity, perceived HBV-related stigma correlated strongly with enacted stigma (r = 0.556) and inversely with having family/friends with HBV (r = -0.059). The 10-item HBV Stigma Scale demonstrated good internal consistency and validity and is suitable for screening for HBV-related stigma in Sierra Leone. The psychometric properties of the scale can be optimized with item additions/modifications and confirmatory factor analysis. The scale may help in combating stigma as a barrier to achieving HBV global elimination goals.
Title: Measuring Stigma Associated with Hepatitis B Virus Infection in Sierra Leone: Validation of an Abridged Berger HIV Stigma Scale
Description:
ABSTRACT Stigma associated with hepatitis B virus (HBV) is common in endemic countries; however; instruments are lacking to accurately measure HBV-related stigma.
We therefore aimed to develop and validate a concise instrument for measuring perceived HBV-related stigma in Sierra Leone.
We enrolled 220 people living with HBV (PWHB) aged ≥ 18 years from August to November 2022.
The initial Likert-scale instrument entailed 12 items adapted from Berger’s HIV Stigma Scale.
We included 4 additional items adapted from the USAID indicators for enacted stigma.
The proposed scale’s psychometric properties were assessed.
After item reduction, the final HBV Stigma Scale consisted of 10 items and had good internal consistency (overall Cronbach’s α = 0.
74), discriminant and construct validity.
Exploratory factor analysis produced a 3-dimensional structure accounting for 59.
3% of variance: personalized stigma driven by public attitudes (6 items), negative self-image (2 items), and disclosure concerns (2 items).
Overall, 72.
8% of respondents reported perceived HBV stigma (mean score 29.
11 ± 4.
14) and a similar a proportion (73.
6%) reported at least one instance of enacted stigma.
In assessing criterion-related validity, perceived HBV-related stigma correlated strongly with enacted stigma (r = 0.
556) and inversely with having family/friends with HBV (r = -0.
059).
The 10-item HBV Stigma Scale demonstrated good internal consistency and validity and is suitable for screening for HBV-related stigma in Sierra Leone.
The psychometric properties of the scale can be optimized with item additions/modifications and confirmatory factor analysis.
The scale may help in combating stigma as a barrier to achieving HBV global elimination goals.

Related Results

The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract Introduction Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
To assess possible role of testing for IgM-specific antibody in the diagnosis and monitoring of patients with hepatitis C, we tested sera from 14 patients with acute and 97 patient...
Evaluasi peningkatan pengetahuan tentang HIV/AIDS dan sikap terhadap ODHA di SMK Gelora Jaya Nusantara
Evaluasi peningkatan pengetahuan tentang HIV/AIDS dan sikap terhadap ODHA di SMK Gelora Jaya Nusantara
Background: HIV/AIDS remains a global health problem in Indonesia, with major barriers being misunderstandings, social stigma, and ineffective educational approaches. The level of ...
Prevalence of Hepatitis C Virus Infection in Hemodialysis Patients: A Longitudinal Study Comparing the Results of RNA and Antibody Assays
Prevalence of Hepatitis C Virus Infection in Hemodialysis Patients: A Longitudinal Study Comparing the Results of RNA and Antibody Assays
We longitudinally studied 51 patients from two hemodialysis centers to determine the prevalence of hepatitis C virus infection in hemodialysis patients. Serum samples were tested f...

Back to Top